Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 result for lebrikizumab

  1. Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over [ID4025]

    In development [GID-TA11349] Expected publication date: 10 July 2024